Conflicts of interest: FHC is a paid consultant for Eagle Wellness, LLC. This has been revealed to Wake Forest Baptist Medical Center and is institutionally managed. All other authors have no conflicts to disclose.

INTRODUCTION {#pros23205-sec-0005}
============

Prostate cancer (PCA) is the most common noncutaneous cancer affecting men worldwide, with over a million new cases diagnosed each year. It is well known that PCA incidence and prevalence vary among racial/ethnic groups and, more recently, have been shown to vary with geographic location. PCA rates are six times higher in Western countries than non‐Western countries [1](#pros23205-bib-0001){ref-type="ref"}. Numerous studies suggest that exposure to components of the modern Western diet (MWD) are associated with this elevated risk for PCA [2](#pros23205-bib-0002){ref-type="ref"}. Dietary omega‐6 (n‐6) polyunsaturated fatty acids (PUFAs), such as linoleic acid (LA; 18:2, n‐6) and arachidonic acid (ARA; 20:4, n‐6), have been implicated as potential risk factors for PCA. Pro‐inflammatory eicosanoids derived primarily from ARA, including prostaglandins and leukotrienes, have been demonstrated to promote both PCA development and progression in well characterized in vitro studies and in vivo animal models [3](#pros23205-bib-0003){ref-type="ref"}, [4](#pros23205-bib-0004){ref-type="ref"}, [5](#pros23205-bib-0005){ref-type="ref"}, [6](#pros23205-bib-0006){ref-type="ref"}, [7](#pros23205-bib-0007){ref-type="ref"}. However, despite extensive experimental data linking n‐6 PUFAs to PCA, the impact of dietary n‐6 PUFAs remains controversial, due in large part to inconsistent epidemiologic studies [8](#pros23205-bib-0008){ref-type="ref"} with the majority finding no association between dietary n‐6 PUFAs and PCA in humans [9](#pros23205-bib-0009){ref-type="ref"}.

Long chain (LC; \>20 carbons) n‐6 PUFAs, such as ARA, can be obtained preformed in the diet or synthesized via the enzymatic conversion of LA, an essential (18 carbon, 18C‐) n‐6 PUFA (Fig. [1](#pros23205-fig-0001){ref-type="fig"}). This biosynthetic pathway utilizes a series of alternating desaturation and elongation steps. The desaturation reactions have long been known to be the rate limiting steps in this pathway [10](#pros23205-bib-0010){ref-type="ref"} and the enzymes that catalyze these reactions are encoded by the fatty acid desaturase 1 and 2 (i.e., *FADS1* and *FADS2*) genes in a region of chromosome 11 known as the *FADS* cluster (11Q12.2‐q13) [11](#pros23205-bib-0011){ref-type="ref"}. These same enzymes also serve as regulatory enzymes for the metabolism of the essential omega‐3 (n‐3) 18C‐PUFA, α‐linolenic acid (ALA; 18:3, n‐3), to n‐3 LC‐PUFAs including eicosapentaenoic acid (EPA; 20:5, n‐3), docosapentaenoic acid (DPA; 22:5, n‐3), and docosahexaenoic acid (DHA; 22:6, n‐3) (Fig. [1](#pros23205-fig-0001){ref-type="fig"}) [12](#pros23205-bib-0012){ref-type="ref"}, [13](#pros23205-bib-0013){ref-type="ref"}.

![Biochemical pathway for the conversion of essential (18 carbon) n‐6 and n‐3 PUFA to LC‐PUFA.](PROS-76-1182-g001){#pros23205-fig-0001}

The conversion of 18C‐PUFAs to LC‐PUFAs has traditionally been considered to be inefficient and thus contribute little to overall tissue levels of LC‐PUFAs. However, recent studies have revealed that genetic and epigenetic variability within the *FADS* cluster impacts the expression of *FADS* genes [14](#pros23205-bib-0014){ref-type="ref"}, [15](#pros23205-bib-0015){ref-type="ref"}, cellular and circulating levels of LC‐PUFAs [16](#pros23205-bib-0016){ref-type="ref"}, [17](#pros23205-bib-0017){ref-type="ref"}, and the efficiency by which individuals convert n‐6 18C‐PUFAs to LC‐PUFAs, particularly ARA [18](#pros23205-bib-0018){ref-type="ref"}, [19](#pros23205-bib-0019){ref-type="ref"}. Importantly, this work has also demonstrated that human ancestry plays a vital role in determining the frequency of these variants, with populations of African ancestry having much higher frequencies of variants associated with efficient LC‐PUFA biosynthesis resulting in increased circulating ARA concentrations [20](#pros23205-bib-0020){ref-type="ref"}, [21](#pros23205-bib-0021){ref-type="ref"}. With regard to the potential impact of these variations on disease phenotypes, studies to date have primarily focused on coronary artery disease (CAD) and brain function, and have not examined the implications of *FADS* variations on cancer development and progression.

Considering the large number of in vitro and in vivo animal studies showing a powerful relationship between ARA and PCA development and the marked differences in the prevalence and development of PCA in distinct racial/ethnic populations, we hypothesized that these genetic and epigenetic variants will affect the risk of PCA in humans. To begin to test this hypothesis, the current study has examined the associations between these *FADS* genetic and epigenetic variants and PUFA metabolism in PCA tissue from patients undergoing radical prostatectomy.

MATERIALS AND METHODS {#pros23205-sec-0006}
=====================

Prostate Tissue Procurement {#pros23205-sec-0007}
---------------------------

The Wake Forest Baptist Health Comprehensive Cancer Center maintains a tumor tissue bank of frozen surgical samples approved for research use. Under a protocol approved by the Wake Forest School of Medicine Institutional Review Board, we queried the tumor tissue bank PCA specimens from patients undergoing radical prostatectomy and identified 60 (N = 60) samples of sufficient quality and quantity to be used for fatty acid (FA), genotype, and pyrosequencing analysis. These samples consisted of 55 European American, 4 African American, and 1 Asian American donor (Table [I](#pros23205-tbl-0001){ref-type="table"}). The median age was 60 years with a median Gleason score of 6. The Gleason score was not available for four samples. No information was available for these patients' serum prostate specific antigen concentration, clinical course, or post‐surgical follow‐up.

###### 

Demographics of the Patient Population

                     Total (N = 60)   GG (N = 27)   GT (N = 21)   TT (N = 12)   *P*
  ------------------ ---------------- ------------- ------------- ------------- ------
  Age                60 (55, 64)      60 (55, 65)   59 (53, 63)   60 (56, 63)   0.67
  Race                                                                          
  Caucasian          55 (91.67%)      22 (81.5%)    21 (100%)     12 (100%)     0.15
  African American   4 (6.67%)        4 (14.8%)     --            --            
  Asian              1 (1.67%)        1 (3.7%)      --            --            
  Gleason Score                                                                 
  \<6                2 (3%)           2 (7%)        --            --            0.32
  6                  35 (58%)         13 (48%)      13 (62%)      9 (75%)       
  7                  19 (32%)         10 (37%)      7 (33%)       2 (17%)       
  \>7                0                                                          

PCA tissue was obtained from patients with the following characteristics. Kruskal--Wallis and chi‐square tests were used to evaluate differences between genotypes. Age is presented as median (interquartile range), race and Gleason score are presented as number (percent of total).
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Fatty Acid Analysis {#pros23205-sec-0008}
-------------------

Fatty acids (FAs) were extracted from PCA tissue and measured as fatty acid methyl esters (FAMEs). FAMEs were prepared following a modification of the protocol by Metcalfe et al. [22](#pros23205-bib-0022){ref-type="ref"}, as previously described [20](#pros23205-bib-0020){ref-type="ref"}, [23](#pros23205-bib-0023){ref-type="ref"}. Briefly, prostate tissue samples were thawed and homogenized in distilled water at 100 mg tissue/ml. One hundred microgram (100 μg) of triheptadecanoin (a triglyceride of C17:0; NuChek Prep, Elysian, MN) was added to homogenates as an internal standard. Total fatty acids were extracted by base hydrolysis and then derivatized under alkaline conditions in methanol in the presence of boron trifluoride (5 min, 100°C) to form FAMEs. FAMEs were analyzed on an Agilent J&W DB‐23 column (30 m × 0.25 mm ID, film thickness 0.25 µm) using an HP 5890 gas chromatography (GC) with a flame ionization detector (FID). Individual FAs were identified by their elution times relative to authenticated FA standards. Twenty‐four FAs, which account for 99% of the total FAs within the extract, were routinely identified from these tissue samples. FA quantities were determined by their relative abundance to that of the added C17:0 internal standard. Individual FA concentrations were expressed as the percentage of each FA relative to the total FA concentration within each sample.

Genotype at Rs174537 {#pros23205-sec-0009}
--------------------

DNA was isolated from archived tissues as previously described [20](#pros23205-bib-0020){ref-type="ref"}. The genotype at rs174537 was determined for each individual as part of a larger panel of 77 SNPs from six fatty acid candidate genes (*FADS1*, *FADS2*, *ELOVL2*, *ELOVL5*, *ACAD11*, and *ACOX1*). Rs174537 was chosen because it has been shown in a large genome‐wide association study (GWAS) to be the strongest genetic determinant associated circulating plasma ARA levels (*P* = 5.95 × 10^−46^) [24](#pros23205-bib-0024){ref-type="ref"}. Additionally, frequency differences in genotypes at rs174537 between African‐Americans and European‐Americans have been shown to be highly associated with differences in LC‐PUFA levels in circulating (serum and plasma) lipids between the two populations [20](#pros23205-bib-0020){ref-type="ref"}, [21](#pros23205-bib-0021){ref-type="ref"}. SNP genotyping was performed with the Sequenom iPlex genotyping system, using the manufacturer\'s instructions (Sequenom, Inc., San Diego, CA). The primers for this assay were 5′ Capture: 5′‐ ACGTTGGATGAGCACCATGTCTGCTGTGTG‐3′; 3′ Capture: 5′‐ ACGTTGGATGAGCCCTGTCGCCCTGCAGAA‐3′; Extend: 5′‐ ACGTCGCCCTGCAGAAGAGACAG‐3′.

Methylation Status of Cg2736326 {#pros23205-sec-0010}
-------------------------------

Cg27386326 is a CpG site located within the *FADS* cluster, between the proximal promoters of *FADS1* and *FADS2*, in a region with an "enhancer" signature. We recently demonstrated that the methylation status of cg27386326 is highly associated with surrogate markers of *FADS* metabolic activity in liver tissue [18](#pros23205-bib-0018){ref-type="ref"}. Genomic DNA (1 µg) from each individual was treated with sodium bisulfite using the EZ 96‐DNA methylation kit (Zymo Research, CA), following the manufacturer\'s standard protocol. To assay the cg27386326 CpG site, pyrosequencing with the cg27386326_04_PM assay was used with a PyroMark Q96 MD (Qiagen, Inc.). Methylation was then quantitated with Pyro Q‐CpG (version 1.0.9; Biotage, Inc.).

Statistical Analysis {#pros23205-sec-0011}
--------------------

Analysis of variance (ANOVA) and nonparametric (Kruskal--Wallis) statistical tests were used to compare the means and medians between genotypes, respectively. Chi‐square tests were used to evaluate proportions between groups. Post hoc pairwise comparisons were made using Tukey or Bonferroni tests. The correlation between the degree of methylation at cg27386326 and FAs (expressed as a percentage of total FAs) and FA ratios were analyzed using Pearson\'s correlation. All statistical analyses were conducted in STATA (IC12.1, College Station, TX) with significance set at the 0.05 level.

RESULTS {#pros23205-sec-0012}
=======

Table [I](#pros23205-tbl-0001){ref-type="table"} shows the distribution of genotypes among the 60 PCA tissue samples. The distribution in Caucasian donors revealed more individuals in the TT genotype than anticipated from previous Caucasian cohorts (22% vs. ∼11% anticipated). However, this genotypic distribution was not significantly different from expected values (*P* = 0.162) and the observed difference is likely due to the limited sample size.

Examination of the overall distribution of FAs in the PCA samples (Table [II](#pros23205-tbl-0002){ref-type="table"}) showed palmitic acid, stearic acid, oleic acid, LA, and ARA to be the primary FAs within the tissue. ARA was the primary n‐6 LC‐PUFA and comprised 15.8% of the total FAs within the tissue. DHA and DPA were the primary n‐3 LC‐PUFAs in the tissue representing 2.9% and 1.2% of the total FAs, respectively. There was a high ratio of n‐6 LC‐PUFA products, ARA and its elongation product adrenic acid (ADA; 22:4, n‐6), to the n‐6 18C‐PUFA precursor, LA, (1.7) and a similarly high ratio of n‐3 LC‐PUFA products, DHA and DPA, to the n‐3 18C‐PUFA precursor, ALA (51.3). The distribution of PUFAs and product to precursor ratios suggest that PCA tissue efficiently synthesizes and accumulates biologically active LC‐PUFAs such as ARA and DHA.

###### 

Impact of Rs174537 Genotype on the Fatty Acid Composition of PCA Tissue

  \% Fatty acid                Total (N = 60)          GG (N = 27)             GT (N = 21)             TT (N = 12)               *P*
  ---------------------------- ----------------------- ----------------------- ----------------------- ------------------------- ------------
  C14:0 \[myristolate\]        0.42 (0.25, 0.49)       0.42 (0.23, 0.51)       0.44 (0.35, 0.47)       0.34 (0.11, 0.46)         0.47
  C14:1 \[myristoleic\]        --                      --                      --                      --                        --
  C15:0                        0 (0, 0.12)             0 (0, 0.19)             0 (0,0)                 0 (0, 0.13)               0.09
  C16:0 \[palmitic\]           21.1 (20.6, 21.7)       20.9 (20.1, 21.3)       21.4 (21, 22.6)         21.6 (20.5, 22.1)         0.09
  C16:1 \[palmitoleic\]        0.59 (0.46, 0.72)       0.58 (0.47, 0.73)       0.59 (0.41, 0.71)       0.63 (0.47, 0.90)         0.68
  **C18:0 \[stearic\]**        **16.1 (15.3, 17.1)**   **16.6 (15.5, 17.8)**   **15.4 (14.9, 16.4)**   **15.8 (15.3, 16.0)**     **0.03**
  C18:1n‐9t \[elaidic\]        0 (0, 0.3)              0 (0, 0.3)              0 (0, 0.27)             0 (0, 0.31)               0.98
  **C18:1n‐9c \[oleic\]**      **19.1 (17.3, 20.8)**   **18.2 (15.6, 20.1)**   **18.4 (17.7, 20.6)**   **21 (20.05, 21.6)**      **0.01**
  C18:1n‐11c                   3 (2.64, 3.25)          2.91 (2.52, 3.12)       3.08 (2.81, 3.32)       3.14 (2.56, 3.94)         0.31
  **C18:2n‐6c \[linoleic\]**   **10.6 (9.77, 11.4)**   **10.5 (9.86, 11.2)**   **9.87 (8.86, 11.3)**   **11.3 (10.8, 12.7)**     **0.02**
  C18:3n‐6 \[GLA\]             --                      --                      --                      --                        --
  C18:3n‐3 \[ALA\]             0.08 (0,0)              0.07 (0,0)              0.11 (0,0)              0.12 (0,0)                0.62
  C18:4n‐3 \[SDA\]             --                      --                      --                      --                        --
  C20:0 \[arachidic\]          0.32 (0, 0.41)          0.33 (0, 0.43)          0.31 (0.13, 0.40)       0.31 (0, 0.41)            0.84
  C20:1n‐9                     0.89 (0.57, 1.17        0.71 (0.44, 1.14)       0.91 (0.76, 1.18)       1.09 (0.74, 1.36)         0.09
  C20:2n‐6                     0.95 (0.72, 1.14)       0.83 (0.7, 1.12)        0.95 (0.72, 1.14)       1 (0.91, 1.24)            0.27
  **C20:3n‐6 \[DGLA\]**        **2.82 (2.4, 3.34)**    **2.52 (2.19, 2.82)**   **3 (2.7, 3.56)**       **3.27 (3.12, 3.89)**     **0.0001**
  **C20:4n‐6 \[ARA\]**         **15.8 (14, 17.6)**     **17.4 (15.1, 18.5)**   **15.7 (13.9, 17.1)**   **13.08 (12.4, 14.2)**    **0.0002**
  C20:5n‐3 \[EPA\]             0.03 (0, 0.22)          0.064 (0, 0.22)         0.11 (0, 0.25)          0.24 (0, 0.18)            0.56
  C22:0 \[behenic\]            0 (0, 0.19)             0 (0, 0.21)             0 (0, 0.19)             0 (0, 0.14)               0.96
  C22:1n‐9 \[euricic\]         0.24 (0.04, 0.29)       0.24 (0, 0.28)          0.23 (0, 0.29)          0.28 (0.18, 0.38)         0.23
  **C22:4n‐6 \[adrenic\]**     **2.14 (1.78, 2.55)**   **2.32 (2.16, 2.63)**   **2.06 (1.74, 2.28)**   **1.77 (1.43, 1.91)**     **0.0016**
  C22:5n‐6                     0.52 (0.33, 0.77)       0.45 (0.24, 0.65)       0.56 (0.44, 0.89)       0.54 (0.26, 0.77)         0.44
  **C22:5n‐3 \[DPA\]**         **1.22 (0.93, 1.41)**   **1.32 (1.09, 1.62)**   **1.19 (0.99, 1.45)**   **0.89 (0.69, 1.07)**     **0.006**
  **C22:6n‐3 \[DHA\]**         **2.89 (2.27, 3.66)**   **3.05 (2.68, 3.89)**   **3.05 (2.04, 3.52)**   **2.11 (1.79, 3)**        **0.03**
  **Total n‐6/Total n‐3**      **7.84 (6.19, 9.32)**   **7.45 (6.04, 8.78)**   **7.33 (6.23, 8.28)**   **10.24 (7.83, 11.74)**   **0.0281**
  Total LC n‐6/LC n‐3          5.32                    5.01                    5.34                    5.99                      0.2494

Fatty acids were expressed as percentage of a given fatty acid relative to total fatty acids within PCA tissue. Levels of individual fatty acids were tested for their potential association with genotype at rs174537. Median and interquartile range are presented and *P*‐values determined using Kruskal--Wallis test. Fatty acids showing a statistically significant relationship with the genotype at rs174537 are highlighted in bold.
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Table [II](#pros23205-tbl-0002){ref-type="table"} also illustrates the distribution of FA as a function of the genotype at rs174537. The presence of the G allele was significantly associated with higher levels of both n‐6 and n‐3 LC‐PUFAs including ARA, ADA, DPA, and DHA and lower levels of dihomo‐γ‐linolenic acid (DGLA; 20:3, n‐6). Twenty‐seven percent of the variations in ARA levels within PCA tissues were found to be attributable to differences in genotype at rs174537. Post hoc pairwise comparisons between genotypes revealed that the mean difference in ARA levels between genotypes GT and TT was −2.35 (*P* = 0.019) and genotypes GG and TT was −3.85 (*P* \< 0.0001). Similarly, the mean difference in DHA levels between GG and TT genotypes was −0.75 (*P* = 0.03). Figure [2](#pros23205-fig-0002){ref-type="fig"} shows the relationship between rs174537 genotypes and the levels of the most abundant PUFAs in PCA tissue. When focusing on the n‐6 PUFAs, the G allele was positively associated with ARA and ADA levels and negatively associated with levels of LA and DGLA. The G allele was also positively related to the n‐3 LC‐PUFAs, DPA, and DHA. While there were significant associations between average LC‐PUFA concentrations and genotypes at rs174537, substantial variation remained between individuals within each genotype (Fig. [2](#pros23205-fig-0002){ref-type="fig"}).

![Relationship between the major PUFA and the genotype at rs174537 in PCA tissue. The concentration of individual PUFA, expressed as a percent of total tissue fatty acids, are analyzed as a function of the rs174537 genotype. *P* values were calculated by Kruskal--Wallis test and presented below.](PROS-76-1182-g002){#pros23205-fig-0002}

An estimate of the overall efficiency of the n‐6 PUFA metabolic pathway was determined by calculating the ratio of measurable terminal products (ARA and ADA) to that of the initial precursor (LA). In addition, DGLA can be used with ARA as a product precursor pair to estimate the efficiency of *FADS1* activity. Figure [3](#pros23205-fig-0003){ref-type="fig"} reveals that there is a strong rs174537 genotype‐dependent relationship between products and precursors for the efficiency of the overall pathway as well as for *FADS1* activity.

![Ratio of products to precursors in the n‐6 PUFA pathway. *P* values were calculated by the Kruskal--Wallis test and are presented below.](PROS-76-1182-g003){#pros23205-fig-0003}

To further examine the variation of PUFA levels within PCA tissue, we evaluated the association between the methylation status of the CpG site, cg27386326, and PUFA concentrations. The dynamic range for methylation at this site was found to be from 75% to 100% in PCA tissue samples. Figure [4](#pros23205-fig-0004){ref-type="fig"} illustrates that the methylation status at cg27386326 was negatively correlated with ARA concentrations. Additionally, the methylation status of this site was negatively correlated with the ratio of ARA + ADA to LA (a marker for the efficiency of the n‐6 biosynthetic pathway) and the ratio of ARA to DGLA (a marker for the efficiency of *FADS1*). These data indicate that like liver tissue, the methylation status of cg27386326 is highly associated with capacity of PCA tissue to synthesize LC‐PUFAs.

![Relationship between the DNA methylation status at cg27386326 and ARA (**A**) and product to precursor (ARA + Adrenic Acid/LA \[**B**\]; and ARA/DGLA \[**C**\]) ratios. Statistical significance was tested using Pearson\'s correlation with *P* values shown below.](PROS-76-1182-g004){#pros23205-fig-0004}

DISCUSSION {#pros23205-sec-0013}
==========

The current study examined whether known genetic and epigenetic variants in the *FADS* cluster impact PUFA levels and the capacity of PCA to produce LC‐PUFAs. PCA tissues were found to have high levels of ARA (∼16% of total FAs) regardless of genotype or methylation status. For comparison, tissues such as brain, cardiac, and inflammatory cells (neutrophils and macrophage), which are conventionally considered to have some of the highest ARA concentrations in humans, have ARA concentrations that range from 5% to 15% of total FAs [25](#pros23205-bib-0025){ref-type="ref"}, [26](#pros23205-bib-0026){ref-type="ref"}, [27](#pros23205-bib-0027){ref-type="ref"}, [28](#pros23205-bib-0028){ref-type="ref"}. This together with the high ratio of ARA/LA suggests that PCA tissue has a large capacity to synthesize ARA from LA. Importantly, there were strong associations between the status of genotype at rs174537 as well as methylation at cg27386326 and levels of LC‐PUFAs and PUFA product to precursor ratios. Together, this suggests that the capacity of individuals to synthesize LC‐PUFAs, such as ARA, in a tissue such as the prostate is both more efficient and variable than previously believed.

Over the past decade, numerous studies have demonstrated that *FADS* variants have an important impact on PUFA concentrations (especially ARA), ratios of PUFA products to precursors, and a number of important molecular and clinical phenotypes [29](#pros23205-bib-0029){ref-type="ref"}. *FADS* haplotypes that favor LC‐PUFA biosynthesis have been associated with oxidative products of ARA and elevated markers for inflammation and CAD [30](#pros23205-bib-0030){ref-type="ref"}, [31](#pros23205-bib-0031){ref-type="ref"}, [32](#pros23205-bib-0032){ref-type="ref"}. To date, the impact of *FADS* variation on cancer has not been examined in humans. Pre‐clinical animal and some clinical studies provide evidence that altering n‐3/n‐6 ratios and ARA metabolism to eicosanoids have the potential to mediate the development and progression of several cancers including those of colon, prostate, and breast [8](#pros23205-bib-0008){ref-type="ref"}, [33](#pros23205-bib-0033){ref-type="ref"}, [34](#pros23205-bib-0034){ref-type="ref"}. Additionally, chronic inflammation is considered an initiating step in the development of many cancers, including PCA [35](#pros23205-bib-0035){ref-type="ref"}. However, results from the majority of epidemiologic studies for each of these cancers fail to detect associations between dietary PUFAs and cancer risk [9](#pros23205-bib-0009){ref-type="ref"}, [36](#pros23205-bib-0036){ref-type="ref"}, [37](#pros23205-bib-0037){ref-type="ref"}. We postulate that genetic and epigenetic variations in the *FADS* cluster may be significant confounders to the results and interpretations of these epidemiologic studies.

It is important to note that the current study did not have access to dietary PUFA information from the PCA tissue donors and thus, a limitation of the study is that it is not possible to model the dietary component of potential gene--diet interactions. However, it is well established that LA found in vegetable oil products (soybean, corn, palm, and canola oils as well as margarine and shortenings) is by far the most abundant PUFA in the MWD, contributing more than 90% of ingested PUFAs and 7--9% of food energy consumed [38](#pros23205-bib-0038){ref-type="ref"}. According to Blasbalg and colleagues, the "most striking modification of the US food supply during the 20th century was the 1,000‐fold increase in the estimated per capita consumption of soybean oil from 0.006% to 7.38% of energy" [38](#pros23205-bib-0038){ref-type="ref"}. Greater than 50% of the total FAs in most soybean oils is LA. It has been shown that this dramatic increase in dietary LA has led to marked increases in circulating LA that can serve as substrate for conversion, in tissues that have the capacity, to LC‐PUFAs such as ARA [38](#pros23205-bib-0038){ref-type="ref"}. Additionally, it has been speculated that this increase in LA consumption is a key component in the MWD that has the capacity to elevate the risk for PCA [39](#pros23205-bib-0039){ref-type="ref"}, [40](#pros23205-bib-0040){ref-type="ref"}, [41](#pros23205-bib-0041){ref-type="ref"}.

Numerous factors can complicate studies that examine the association of dietary PUFA intake with disease risk. Dietary PUFAs, once consumed, reside in multiple pools of circulating lipids and are metabolized to LC‐PUFAs by target tissues such as the liver and fat. Until recently, the bioconversion of dietary 18C‐PUFAs to LC‐PUFAs was thought to be minimal (\<1% efficient) and uniform across all human populations. However, as demonstrated in this study, there are genetic and epigenetic variants that impact tissue LC‐PUFA concentrations and the efficiency at which circulating PUFAs are converted to LC‐PUFAs. If *FADS* variants and cellular levels ARA impact the capacity of PCA tissue to make eicosanoids, as has been shown in whole blood [42](#pros23205-bib-0042){ref-type="ref"}, then altered ARA levels associated with these variants could play an important role in eicosanoid‐mediated PCA development and progression.

Additionally, it is now recognized that certain populations (e.g., African ancestry) have much higher frequencies of *FADS* variants associated with increased LC‐PUFA biosynthesis. A GWAS that included five cohorts with ∼8,000 African Americans confirmed the importance of the *FADS* cluster in affecting circulating PUFA and CAD biomarker concentrations across populations [43](#pros23205-bib-0043){ref-type="ref"}. These factors can confound studies that attempt to study the relationship between dietary FAs and disease outcomes. They may also provide a genetic basis for gene--diet interactions that result in PCA and other health disparities in certain racial/ethnic populations.
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